# The Role of A-Kinase Anchoring Proteins for Inhibitory cAMP Signalling in Platelets

## TL;DR

This paper reviews how A-kinase anchoring proteins (AKAPs) regulate cAMP signaling in platelets, potentially offering new ways to prevent blood clots.

## Contribution

The paper provides a comprehensive review of AKAPs in platelets and their role in cAMP signaling, suggesting their potential as therapeutic targets.

## Key findings

- AKAPs coordinate cAMP signaling and platelet inhibition in a spatial and temporal manner.
- AKAPs may serve as new therapeutic targets to prevent thrombus formation via endogenous cAMP signaling.

## Abstract

What are the main findings?
A-kinase anchoring proteins (AKAP) are expressed in human platelets.AKAPs provide spatial and temporal coordination of cAMP signalling and platelet inhibition.

A-kinase anchoring proteins (AKAP) are expressed in human platelets.

AKAPs provide spatial and temporal coordination of cAMP signalling and platelet inhibition.

What are the implications of the main findings?
AKAPs fine-tune endothelium-dependent platelet regulation.AKAPs could be new therapeutic targets that prevent thrombus formation through endogenous cAMP signalling.

AKAPs fine-tune endothelium-dependent platelet regulation.

AKAPs could be new therapeutic targets that prevent thrombus formation through endogenous cAMP signalling.

Platelets are small circulating blood cells that mediate haemostasis and thrombosis. Platelets respond to vascular damage by adhesion, granule release, and aggregation. Healthy endothelial cells inhibit platelets through prostacyclin-induced cAMP signalling. Intracellular cAMP activates protein kinase A (PKA), a tetrameric kinase composed of two regulatory (R) and two catalytic (C) subunits. cAMP-binding triggers dissociation of C subunits from the PKA complex and phosphorylation of substrate proteins, which mediate platelet inhibition. The R subunits of PKA are known to be attached to A-kinase anchoring proteins (AKAPs), which enable subcellular compartmentalisation of cAMP signalling. Proteomics have identified 22 AKAPs in platelets, but only a few of these have been studied in detail. This review summarises current knowledge about platelet AKAPs, including studies done regarding other cells. Possible integration of AKAPs into platelet signalling is explored with a focus on subcellular localisation, interaction partners, and PKA-mediated substrate phosphorylation. As main platelet compartments, the plasma membrane, endosomes, mitochondria, the Golgi, the dense tubular system, and the cytoskeleton are considered. Potential roles of individual AKAPs in platelet inhibition are discussed, and open questions in the field are defined.